JP2005529587A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529587A5
JP2005529587A5 JP2003576000A JP2003576000A JP2005529587A5 JP 2005529587 A5 JP2005529587 A5 JP 2005529587A5 JP 2003576000 A JP2003576000 A JP 2003576000A JP 2003576000 A JP2003576000 A JP 2003576000A JP 2005529587 A5 JP2005529587 A5 JP 2005529587A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
binding
composition
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/007647 external-priority patent/WO2003077947A1/en
Publication of JP2005529587A publication Critical patent/JP2005529587A/ja
Publication of JP2005529587A5 publication Critical patent/JP2005529587A5/ja
Pending legal-status Critical Current

Links

JP2003576000A 2002-03-15 2003-03-13 Ｃｄ２００レセプターを調節する方法 Pending JP2005529587A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36451302P 2002-03-15 2002-03-15
PCT/US2003/007647 WO2003077947A1 (en) 2002-03-15 2003-03-13 Methods of modulating cd200 receptors

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2006058745A Division JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134635A Division JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134634A Division JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Publications (2)

Publication Number Publication Date
JP2005529587A JP2005529587A (ja) 2005-10-06
JP2005529587A5 true JP2005529587A5 (https=) 2006-04-20

Family

ID=28041929

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003576000A Pending JP2005529587A (ja) 2002-03-15 2003-03-13 Ｃｄ２００レセプターを調節する方法
JP2006058745A Pending JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134634A Withdrawn JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134635A Withdrawn JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006058745A Pending JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134634A Withdrawn JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134635A Withdrawn JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Country Status (16)

Country Link
US (3) US20030223991A1 (https=)
EP (3) EP2100617A1 (https=)
JP (4) JP2005529587A (https=)
AT (1) ATE439861T1 (https=)
AU (3) AU2003220219A1 (https=)
CA (1) CA2478803A1 (https=)
CY (1) CY1109521T1 (https=)
DE (1) DE60328870D1 (https=)
DK (1) DK1482973T3 (https=)
ES (1) ES2330211T3 (https=)
MX (1) MXPA04008937A (https=)
NZ (2) NZ570998A (https=)
PT (1) PT1482973E (https=)
SI (1) SI1482973T1 (https=)
WO (1) WO2003077947A1 (https=)
ZA (2) ZA200407384B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515382A (en) * 1999-05-13 2004-03-26 Medical Res Council OX2 receptor homologs
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
WO2003103709A2 (en) * 2002-06-07 2003-12-18 Trillium Therapeutics Inc. Modulation of bone development
MXPA05006978A (es) * 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
JP4919453B2 (ja) * 2005-04-07 2012-04-18 独立行政法人理化学研究所 炎症性疾患の予防又は治療剤
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
KR20090094846A (ko) * 2006-12-22 2009-09-08 쉐링 코포레이션 Ｃｄ200ｒ에 대한 항체
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
WO2009004339A2 (en) * 2007-07-03 2009-01-08 Imperial Innovations Limited Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2010135183A1 (en) * 2009-05-20 2010-11-25 Schering Corporation Modulation of pilr receptors to treat sepsis
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
BR112012024565B1 (pt) 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
DK3421486T5 (da) * 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
JP5854432B2 (ja) * 2012-09-28 2016-02-09 森永乳業株式会社 アレルギー反応検出法
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CN109789201B (zh) 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
AR116668A1 (es) * 2018-09-14 2021-06-02 Lilly Co Eli Anticuerpos agonistas contra cd200r y sus usos

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5202267A (en) 1988-04-04 1993-04-13 Hygeia Sciences, Inc. Sol capture immunoassay kit and procedure
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
DE69113162T2 (de) * 1990-08-02 1996-03-14 Hoffmann La Roche Antiallergische Mischung.
US5571702A (en) 1991-03-29 1996-11-05 Genentech, Inc. Amplification method for detection of human PF4A receptors
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6306608B1 (en) 1996-05-27 2001-10-23 Medical & Biological Laboratories Co., Ltd. Anti-human LECT2 antibody, cells producing the same, and method and kit for assaying the same
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JPH10212242A (ja) * 1996-11-27 1998-08-11 Tosoh Corp 新規血小板増多剤
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US5948627A (en) 1997-05-30 1999-09-07 One Lambda Immunobead flow cytometric detection of anti-HLA panel-reactive antibody
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
JPH11246435A (ja) * 1997-10-29 1999-09-14 Ajinomoto Co Inc 免疫調整剤
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
AU5134799A (en) * 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
NZ515382A (en) * 1999-05-13 2004-03-26 Medical Res Council OX2 receptor homologs
AU2001278338A1 (en) * 2000-08-03 2002-02-18 David A Clark Methods and compositions for modulating tumor growth
WO2002088164A1 (en) 2001-04-26 2002-11-07 Immunex Corporation Human ox2 receptors
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
US20040126777A1 (en) * 2002-01-28 2004-07-01 Bhatt Ramesh Rajani Lp mammalian proteins; related reagents
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer

Similar Documents

Publication Publication Date Title
JP2005529587A5 (https=)
JP4964957B2 (ja) 抗薬物抗体アッセイ
RU2014104113A (ru) Elisa для vegf
JP2017524725A5 (https=)
JP2023017841A5 (https=)
RU2015155552A (ru) Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
RU2004136285A (ru) Способ диагностики гепатоцеллюлярной карциномы
JP2007527406A5 (https=)
JP2016505634A5 (https=)
JP2006502416A5 (https=)
JP2008538919A5 (https=)
RU2010117018A (ru) Антитела к gdf8 и их применения
JP2002529705A5 (https=)
JP2007525427A5 (https=)
JP2018535404A5 (https=)
JP2010536043A5 (https=)
RU2014128510A (ru) Способ определения свободного связывающего партнера мультиспецифичного связующего
JP2008545145A5 (https=)
DK1125130T3 (da) Påvisning af syreresistente mikroorganismer i afföringen
RU2017114626A (ru) Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике
Stevenson et al. Analysis of soluble HLA class II antigenic material in patients with immunological diseases using monoclonal antibodies
JP4413179B2 (ja) 免疫学的粒子凝集反応方法
JPWO2020158856A1 (ja) 生物学的試料中の遊離ａｉｍの免疫学的分析方法
WO2020158858A1 (ja) 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法
JP2012153664A (ja) 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法